Table 1. Studies that have examined the effect of neural ablation on cancer development and progression.
| Tumor Type | Ref. | Models Employed | Neural Ablation | Nerves Affected by Treatment | Age of Effective Intervention | Outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GEMM | Xeno | Chem | Surg | Chem | Symp | Para | Sensory | Neonate | Juvenile | Adult | Reduced precancer lesions | Reduced tumor growth | Reduced metastasis | ||
| Prostate | [48] | ✓ | ✓ | ✓ | ✓ | ✓ | (✓) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Stomach | [49] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| PDAC | [11] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ND | |||||||
| BCC | [50] | ✓ | ✓ | (✓) | ✓ | ✓ | ND | ✓ | ND | ||||||
Parentheses indicate small or minor effects on this population of neurons. ND, not determined. PDAC, pancreatic ductal adenocarcinoma; BCC; basal cell carcinoma; GEMM, genetically engineered mouse model; Xeno, xenograft cancer model; Chem, chemically induced cancer; Surg, surgical ablation; Chem, chemical ablation; Symp, postganglionic sympathetic nerves; Para, postganglionic parasympathetic nerves